RxDoctor Payments Data

Zhaodong Li, MD

Gastroenterology · Fort Wayne, INNPI 1043641475

Payments from drug & device makers

$1,095in general payments, 2019–2025

Across 28 payments — averaging $39.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$458
  • AbbVie$159
  • Johnson & Johnson$154
  • Olympus America Inc.$99
  • Takeda Pharmaceuticals U.S.A., Inc.$88
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$56
  • plus $82 from 3 others

What the payments were for

  • Travel & lodging$43740%
  • Food & beverage$65760%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,095 in reported general payments places this provider in the 30th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$38,439
Medicare patients
209
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin13$43,293
CreonLipase/Protease/Amylase15$25,218
LinzessLinaclotide33$24,125
MovantikNaloxegol Oxalate20$10,538
Colestipol Hcl56$5,077
Ursodiol23$3,152
Lubiprostone29$3,137
Pantoprazole Sodium185$1,813
Omeprazole125$1,582
Budesonide DrBudesonide17$981
Esomeprazole Magnesium25$955
Sucralfate21$775
Dicyclomine Hcl37$623
Ondansetron OdtOndansetron18$397
Lansoprazole15$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$159$49,34348 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$56$43,29313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →